Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B
- Arslan, S.
- Dogan, Z.
- Kucukazman, M.
- Poyrazoglu, O. K.
- Biyik, M.
- Ozturk, N. A.
- Aydogan, T.
- Coban, S.
- Kocaman, O.
- Sapmaz, F.
- Gokturk, S. H.
- Demirezer, A.
- Tanoglu, A.
- Yildirim, B.
- Altinbas, A.
- Atak, B. M.
- Cosar, A. M.
- Alkan, E.
- KOÇAK TUFAN, ZELİHA
- Kekilli, M.
- Ataseven, H.
- Purnak, T.
- Basar, O.
- Koklu, N.
- Ozturk, O.
- Karaca, C.
- Besisik, F.
- Unverdi, S.
- Guner, R.
- Bakkaloglu, K.
- Koklu, S.
- Gulsen, M. T.
- Tuna, Y.
- Koklu, H.
- Yuksel, O.
- Demir, M.
- Kockar, C.
Publication date
January 2015
DOI Publisher
Wiley Journal
Alimentary Pharmacology & TherapeuticsAbstract
BackgroundResults are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection
Add to ORKG